Muscle Invasive Bladder Cancer
2 competing products in clinical development for Muscle Invasive Bladder Cancer.
Pipeline by Phase
Phase 22
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | Recruiting | 42 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | UNKNOWN | 31 |